Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial

Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...

P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...

Interferon beta and suicide in multiple sclerosis.

reversible pulmonary artery hypertension in association with interferon-beta therapy for ‎multiple sclerosis

no abstract

Fulminant liver failure during interferon beta treatment of multiple sclerosis.

Although interferon (IFN) b has many adverse effects, including flulike illness, increased spasticity, and laboratory abnormalities,1 autoimmune events are usually limited to autoantibodies with the thyroid the most common target organ involved.2 Liver abnormalities during IFN b therapy are usually clinically asymptomatic and transient biochemical events.1,2 We report a patient who developed ac...